Research Progress of Osteoporosis Drugs and Their Mechanism of Action

Wenbo Hou; Xi Wang; Yanqin Lu

doi:doi:10.11648/j.sd.20221003.28

| Peer-Reviewed

Research Progress of Osteoporosis Drugs and Their Mechanism of Action

Wenbo Hou, Xi Wang, Yanqin Lu

Published in Science Discovery (Volume 10, Issue 3)

Received: 9 June 2022 Accepted: Published: 9 June 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Osteoporosis (OP) is a systemic bone metabolic disease characterized by decreased bone mass, decreased bone density and easy fracture. The number of osteoporosis patients in the world has exceeded 200 million, and the incidence rate has exceeded 25%, ranking the sixth most common and frequently-occurring disease in the world. At present, the methods of treating osteoporosis are mainly drug therapy and non-drug therapy. Medicine can only delay the loss of bone, but it can't restore the lost bone. At present, drugs mainly include drugs that inhibit bone resorption, drugs that promote osteogenesis, and traditional Chinese medicine. Drugs that inhibit bone resorption mainly include bisphosphonate, calcitonin, estrogen, BANKL monoclonal antibody, etc. Drugs that promote bone formation include thyroid hormone, calcium, vitamin D and simvastatin. Single traditional Chinese medicines mainly include Eucommia ulmoides Oliv., Epimedium Epimedium, etc. The prescriptions of traditional Chinese medicines mainly include Longmuzhuanggu granules, Xianlinggubao capsules, etc. Different drugs have different therapeutic effects and unique advantages. How to select the optimal drug to treat different types of osteoporosis has become the focus of clinical treatment. Besides, with the deepening of research and understanding on bone metabolism, the upgrading of existing drugs, the compatible use of drugs with different action mechanisms, new targeted drugs for cell function and gene, and the promotion of traditional Chinese medicine in China are all worthy of research. It is hoped that this research can provide new research ideas for pharmaceutical researchers and help to develop new clinical medication patterns and the R&D and marketing of new drugs.

Published in	Science Discovery (Volume 10, Issue 3)
DOI	10.11648/j.sd.20221003.28
Page(s)	191-199
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Osteoporosis, Inhibition of Bone Resorption, Promote Bone Formation, Double-Acting Drug, Traditional Chinese Medicine

References

[1]	Albright F, Smith PH, Richardson AMJJotAMA: Postmenopausal osteoporosis. Its clinical features. JAMA. 1940, 116 (22): 2465-2474.
[2]	王文汇:抗骨质疏松药物的作用及进展%J中国医刊. 2021, 56 (11): 1189-1192。
[3]	Cummings SR, Martin JS, Mcclung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang AJNEJoM: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. 2009, 361 (8): 756-765.
[4]	Smith MR, Egerdie B, Toriz NH, Feldman R, Lamy OJNEJoM: Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. 2009, 361 (8): 745-755.
[5]	Langdahl BL, Stubbe TC, Pei-Ran H, Roland C, Ed Ward C, Kendler DL, Jean-Yves R, Alan K, Michael LE, Miller PDJJoCE et al: A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. 2015 (4): 1335-1342.
[6]	Eric O, Teglbjrg CS, Langdahl BL, Roland C, Edward C, Kendler DL, Jean-Yves R, Alan K, Michael LE, Miller PDJJCEM: A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. 2012 (9): 3161-3169.
[7]	Anastasilakis AD, Polyzos SA, Makras PJEJoE: THERAPY OF ENDOCRINE DISEASE: Denosumab versus bisphosphonates for the treatment of postmenopausal osteoporosis. 2018, 179 (1): EJE-18-0056.
[8]	Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, J.-Y R, Singer AJJoCE et al: Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. (8): 3163-3170.
[9]	Saag KG, Pannacciulli N, Geusens P, Adachi JD, Lems WFJA, Rheumatology: Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. 2019, 71 (7).
[10]	Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WFJLD et al: Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. 2018: S2213858718300755.
[11]	Chotiyarnwong P, Mccloskey E, Eastell R, Mcclung MR, Cummings SRJJoB, Research M: A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. 2020, 35 (6).
[12]	陈镜,冯正平:骨质疏松症治疗药物研究进展%J中国骨质疏松杂志. 2021, 27 (05): 776-780。
[13]	吴宇龄,齐齐哈尔医学院学报于J:探讨骨质疏松患者采取骨化三醇与双磷酸盐类药物治疗的效果和安全性. 2019, 40 (19): 2。
[14]	Russell RGG, Watts NB, Ebetino FH, Rogers MJJOI: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. 2008, 19 (6): 733-759.
[15]	樊勤学,陆琳松,孙治国,李祖涛,米尔阿里木•木尔提扎,徐阔,王浩,骨科袁J:唑来膦酸治疗原发性骨质疏松症的临床观察. 2014, 5 (2): 3。
[16]	Black DM, Reid IR, Lyles K, Bucci-Rechtweg C, Eastell RJB: Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. 2013, 98 (2): 557-563.
[17]	贾秀娟,贾黎,钟丽娜,中国骨质疏松杂志章J:高龄老年骨质疏松症患者应用唑来膦酸注射液的安全性及疗效初步分析. 2013, 000 (010): 1080-1083。
[18]	Tamara, Isakova, Patricia, Wahl, Gabriela, Vargas, Orlando, International GJK: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. 2011.
[19]	A BC, B DCBJMCP: Oral Bisphosphonates and Upper Gastrointestinal Tract Problems: What Is the Evidence? 2002, 77 (10): 1031-1043.
[20]	Pharmacology JAMTGDEJA, Therapeutics: Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. 2012, 36 (8): 708-716.
[21]	王非,荆莉,石卫峰,药品评价徐J:抗骨质疏松药物的不良反应. 2013 (23): 6。
[22]	Cauley JA, Robbins J, Zhao C, Cummings SR, Watts NBJJotAMA: Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial. 2003, 290 (13): 1729-1738.
[23]	中国骨质疏松杂志张J:雌激素与雌激素受体骨代谢调节作用. 2019, 25 (5): 5。
[24]	刘颖,陈中沛,邓武权,姜友昭,吴绮楠,陈兵,中国老年学杂志王J:黑升麻提取物治疗围绝经期骨质疏松患者的疗效. 2013, 33 (6): 2。
[25]	夏维波,章振林,林华,金小岚,余卫,中国骨质疏松杂志付J:原发性骨质疏松症诊疗指南(2017). 2019。
[26]	Recker RR, Mitlak BH, Xiao N, Krege JHJCMR, Opinion: Long-term raloxifene for postmenopausal osteoporosis. 2011, 27 (9): 1755-1761.
[27]	胡焓,万媛,张书力,乔杰,袁峰,冯丹:雌激素替代疗法联合利塞膦酸钠对绝经期骨质疏松患者疼痛及血清BGP,BAP,E2水平的影响. 2022 (2)。
[28]	武警后勤学院学报：医学版张J:绝经后妇女骨质疏松治疗进展. 2014 (8): 4。
[29]	Ishtiaq S, Fogelman I, Hampson GJJoEI: Treatment of post-menopausal osteoporosis: beyond bisphosphonates. 2015, 38 (1): 13-29.
[30]	杜娟,管慧,刘英,刘慧红,现代生物医学进展林J:鲑鱼降钙素联合糖皮质激素吸入治疗COPD合并骨质疏松的疗效及对血清PINP,β-CTX,MMP-9水平的影响. 2019 (14): 5。
[31]	中国处方药李J:骨质疏松药物治疗研究进展.2018,16(4):2.
[32]	覃丹,丁洁,临床药物治疗杂志凃J:阿法骨化醇联合降钙素治疗骨质疏松症的有效性. 2021, 19 (9): 5。
[33]	李晓辉,魏国贤,李晓萍,张军平,医学理论与实践梁J:老年骨质疏松症患者应用唑来膦酸钠联合鲑鱼降钙素治疗的效果观察. 2021, 34 (21): 3。
[34]	李雪琴,张日恒,郑宇蓝:鲑鱼降钙素+骨化三醇治疗绝经后骨质疏松症的疗效及骨密度情况观察%J黑龙江中医药. 2020, 49 (01): 27-28。
[35]	董冰子,中华骨质疏松和骨矿盐疾病杂志孙J:骨质疏松症治疗新进展:从分子机制到药物靶点. 2018, 11 (6): 8。
[36]	中国骨质疏松杂志张J:甲状旁腺素的生物学研究与成骨作用. 2017, 23 (12): 6。
[37]	Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli J, Darby AJ, Tregear GW, Parsons JAJL: Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. 1976, 307 (7968): 1035-1038.
[38]	季祥,纪泉,孙凤坡,刘军川,刘光年,中华老年医学杂志文J:老年骨质疏松性转子间骨折患者长期使用特立帕肽的效果分析. 2018, 37 (12): 5。
[39]	Yang C, Le G, Lu C, Wei R, Zhan XJM: Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials. 2020, 99 (7): e19042.
[40]	杨德鸿,胡少宇,孟越,童国军,南方医科大学学报陈J:特立帕肽保守治疗骨质疏松性脊柱骨折:12例报告. 2016, 36 (3): 5。
[41]	Antonio, Figliomeni, Viola, Signorini, Maurizio, Clinical MJ, Rheumatology E: One year in review 2018: progress in osteoporosis treatment. 2018.
[42]	Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JPJNRR: Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. 2011, 7 (8):447.
[43]	John, L., Vahle, Gerald, G., Long, George, Sandusky, Michael, Pathology WJT: Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose. 2016.
[44]	孙平,虎松艳,巫培康,蔡妹群,楼慧玲,中国骨质疏松杂志王J:广州地区骨质疏松症患者冬季维生素D水平现状分析. 2016, 22 (6): 4。
[45]	王晶,赵津璋,刘国良,李微,中国医学装备周J:辛伐他汀对去卵巢小鼠骨保护作用的实验研究. 2019, 16 (1): 4。
[46]	张岩,刘昊,邢磊,张国彬,中国组织工程研究田J:辛伐他汀干预卵巢切除大鼠骨密度和生物力学性能的变化. 2016, 20 (7): 6。
[47]	中国老年学杂志刘J:老年2型糖尿病合并骨质疏松患者行唑来膦酸联合辛伐他汀的治疗效果. 2021, 41 (12): 4。
[48]	李杰,上官海燕,陈晓倩,王亚梅,仲彬,临床和实验医学杂志周J:辛伐他汀对更年期糖尿病患者骨密度,骨代谢影响的前瞻性随机对照研究. 2020, 19 (20): 5。
[49]	申红梅,潘兹海,临床研究郭J:对比研究老年高血压合并骨质疏松患者口服依那普利联合辛伐他汀对骨密度及骨代谢指标的效果. 2019, 27 (7): 2。
[50]	何鹏,金一,中国新药杂志马J:治疗骨质疏松新药——依普黄酮. 1999, 8 (010): 670-672。
[51]	Jian-Guo, Chu, Mu-Wei, Dai, Yu, Wang, Fa-Ming, Tian, Hui-Ping, Disorders SJBM: Strontium ranelate causes osteophytes overgrowth in a model of early phase osteoarthritis. 2017.
[52]	朱庆华,陶周善,谢加兵,杨民,大连医科大学学报丁J:甲状旁腺激素1-34和雷奈酸锶联合使用对去势大鼠骨质疏松症影响的研究. 2017, 39 (1): 5。
[53]	Iucif N, Oliveira RZ, Achcar J, Lima CMM, Silvah JH, Marchini JSJJotAGS: Effect of Strontium Ranelate on Bone Metabolism of Elderly Men. 2015, 63 (12): 2634-2635.
[54]	Bolland MJ, Grey AJBO: A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. 2014, 4 (10): e005787.
[55]	Ding XY, Jiang Y, Jia XM, Liu FHJCPJ: Synthesis of Strontium Ranelate,an Antiosteoporosis Drug. 2008, 43 (11): 874-876.
[56]	成都中医学院编:常用中药学:常用中药学; 1971。
[57]	Wang H, Li MC, Jing Y, Dan Y, Su YF, Fan GW, Yan Z, Gao XM, Paoletti RJFC: Estrogenic properties of six compounds derived from Eucommia ulmoides Oliv. and their differing biological activity through estrogen receptors α and β. 2011, 129 (2): 408-416.
[58]	Pan, Yalei, Niu, Yinbo, Chenrui, Zhai, Yuankun, Zhang, Rong, Medicine GJAJoC: Du-Zhong (Eucommia ulmoides) Prevents Disuse-Induced Osteoporosis in Hind Limb Suspension Rats. 2014.
[59]	张维,长春中医药大学学报尹J:鹿茸提取物治疗骨质疏松症研究. 2016 (2): 3。
[60]	王艳双,罗速,张大方,曲晓波,王秀丽,谭寅凤,中草药李J:梅花鹿茸Ⅰ型胶原对破骨细胞的影响及其分子机制. 2013, 044 (024): 3503-3509。
[61]	李时珍:本草纲目.上册:本草纲目.上册; 1982。
[62]	刘章碧,-页严J中年卷期:熟地,黄芪为主药治疗绝经后骨质疏松症的临床观察. 2014。
[63]	汤群芳,孔令军,顾振纶,中草药谢J:蛇床子素抑制大鼠骨质疏松的实验研究. 2006, 37 (11): 3。
[64]	Xu B, Wang X, Wu C, Zhu L, Chen O, Wang X, Gianpaolo PJPO: Flavonoid compound icariin enhances BMP-2 induced differentiation and signalling by targeting to connective tissue growth factor (CTGF) in SAMP6 osteoblasts. 2018, 13 (7): e0200367-.
[65]	段斌斌,万全增,李春雯,中医正骨史J:骨碎补对OPG/RANKL表达影响的研究进展. 2011, 23 (6): 40-42。
[66]	林民贵,中国实用医药肖J:丹参酚酸抗类风湿性关节炎致骨质疏松的实验研究. 2014 (21): 2。
[67]	张晓,张国庆,顾伯林,徐又佳,世界科学技术-中医药现代化姜J:丹参对人成骨细胞骨钙素生成及钙离子浓度的影响. 2013, 15 (2): 274-277。
[68]	胡振波,赵刚,刘惟莞,夏纯,丁虹,世界中医药黄J:龙牡壮骨颗粒对糖皮质激素所致大鼠骨质疏松症作用研究. 2017, 12 (12): 3。
[69]	戴亦晖,中国疗养医学陈J:龙牡壮骨颗粒治疗原发性骨质疏松症的临床观察. 2012, 21 (2): 2。
[70]	傅兰清,胡亚俊,世界中医药王J:龙牡壮骨颗粒在治疗绝经期骨质疏松性椎体压缩性骨折的临床观察. 2017, 12 (5): 5。
[71]	刘美芳,杨锋,云南中医中药杂志曾J:仙灵骨葆胶囊治疗绝经后女性骨质疏松症的疗效观察. 2021, 42 (6): 4。
[72]	陈礼梅,林晓洁,徐嘉辉,胡红艳,中国医学创新杨J:补骨强筋方治疗围绝经期骨质疏松症的疗效及对性激素、炎症因子的影响. 2019, 16 (36): 5。
[73]	罗娟,胡永善,吴毅,中国康复医学杂志孙J:补肾健脾中药治疗骨质疏松症疗效观察. 2007, 22 (10): 2。
[74]	蒋淑媛,尤田,中国骨质疏松杂志张J:中药卫骨胶囊治疗骨质疏松症的临床观察. 2002, 8 (4): 3。
[75]	陈伦,祁佳,中国骨质疏松杂志陶J:强骨胶囊联合降钙素治疗骨质疏松的系统评价. 2019, 25 (11): 6。
[76]	世界复合医学侯J:分析老年性骨质疏松症患者应用强骨胶囊联合温针灸治疗的价值. 2020 (1): 4。
[77]	薛英,中华生物医学工程杂志郝J:强骨胶囊经p38-丝裂原活化的磷酸激酶信号通路对膝关节骨性关节炎的作用机制. 2021, 27 (5): 6。
[78]	李旭艳:强骨胶囊治疗类风湿性关节炎并发骨质疏松的临床效果及安全性分析%J内蒙古中医药. 2021, 40 (7)。
[79]	梁爽,王忠霞,刘西哲,河北医药潘J:金天格胶囊治疗老年骨质疏松症的疗效观察. 2021, 43 (10): 4。
[80]	成洁,王颖,吉健华,宋欣丽,陕西中医黄J:骨疏康胶囊治疗肾阳虚型骨质疏松症疗效及对患者骨代谢影响. 2019, 40 (9): 4。
[81]	李宝红,吴劲东,赵文昌,辽宁中医药大学学报宋J:护骨胶囊对成骨细胞增殖、分化影响. 2013, 15 (10): 3。
[82]	谢雁鸣,刘峘,姜俊杰,魏戌,申浩,支英杰,孙晶,李晋玉,包晓霞,中国中药杂志师J:绝经后骨质疏松症中医临床实践指南(征求意见稿). 2021, 46 (22): 7。
[83]	王金台,王淑玲,中国实用医药郝J:金乌骨通胶囊治疗绝经后骨质疏松的临床研究. 2008, 3 (34): 2。
[84]	孙以成,中国骨质疏松杂志林J:骨愈灵胶囊对绝经后骨质疏松症的疗效及骨代谢指标的影响. 2020, 26 (3): 4。
[85]	Drugs EDJ, Aging: Denosumab: A Review in Postmenopausal Osteoporosis. 2018, 35 (21): 163.

Cite This Article

Plain Text BibTeX RIS

APA Style

Wenbo Hou, Xi Wang, Yanqin Lu. (2022). Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Science Discovery, 10(3), 191-199. https://doi.org/10.11648/j.sd.20221003.28

Copy | Download

ACS Style

Wenbo Hou; Xi Wang; Yanqin Lu. Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Sci. Discov. 2022, 10(3), 191-199. doi: 10.11648/j.sd.20221003.28

Copy | Download

AMA Style

Wenbo Hou, Xi Wang, Yanqin Lu. Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Sci Discov. 2022;10(3):191-199. doi: 10.11648/j.sd.20221003.28

Copy | Download

@article{10.11648/j.sd.20221003.28,
  author = {Wenbo Hou and Xi Wang and Yanqin Lu},
  title = {Research Progress of Osteoporosis Drugs and Their Mechanism of Action},
  journal = {Science Discovery},
  volume = {10},
  number = {3},
  pages = {191-199},
  doi = {10.11648/j.sd.20221003.28},
  url = {https://doi.org/10.11648/j.sd.20221003.28},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20221003.28},
  abstract = {Osteoporosis (OP) is a systemic bone metabolic disease characterized by decreased bone mass, decreased bone density and easy fracture. The number of osteoporosis patients in the world has exceeded 200 million, and the incidence rate has exceeded 25%, ranking the sixth most common and frequently-occurring disease in the world. At present, the methods of treating osteoporosis are mainly drug therapy and non-drug therapy. Medicine can only delay the loss of bone, but it can't restore the lost bone. At present, drugs mainly include drugs that inhibit bone resorption, drugs that promote osteogenesis, and traditional Chinese medicine. Drugs that inhibit bone resorption mainly include bisphosphonate, calcitonin, estrogen, BANKL monoclonal antibody, etc. Drugs that promote bone formation include thyroid hormone, calcium, vitamin D and simvastatin. Single traditional Chinese medicines mainly include Eucommia ulmoides Oliv., Epimedium Epimedium, etc. The prescriptions of traditional Chinese medicines mainly include Longmuzhuanggu granules, Xianlinggubao capsules, etc. Different drugs have different therapeutic effects and unique advantages. How to select the optimal drug to treat different types of osteoporosis has become the focus of clinical treatment. Besides, with the deepening of research and understanding on bone metabolism, the upgrading of existing drugs, the compatible use of drugs with different action mechanisms, new targeted drugs for cell function and gene, and the promotion of traditional Chinese medicine in China are all worthy of research. It is hoped that this research can provide new research ideas for pharmaceutical researchers and help to develop new clinical medication patterns and the R&D and marketing of new drugs.},
 year = {2022}
}

Copy | Download

TY - JOUR
T1 - Research Progress of Osteoporosis Drugs and Their Mechanism of Action
AU - Wenbo Hou
AU - Xi Wang
AU - Yanqin Lu
Y1 - 2022/06/09
PY - 2022
N1 - https://doi.org/10.11648/j.sd.20221003.28
DO - 10.11648/j.sd.20221003.28
T2 - Science Discovery
JF - Science Discovery
JO - Science Discovery
SP - 191
EP - 199
PB - Science Publishing Group
SN - 2331-0650
UR - https://doi.org/10.11648/j.sd.20221003.28
AB - Osteoporosis (OP) is a systemic bone metabolic disease characterized by decreased bone mass, decreased bone density and easy fracture. The number of osteoporosis patients in the world has exceeded 200 million, and the incidence rate has exceeded 25%, ranking the sixth most common and frequently-occurring disease in the world. At present, the methods of treating osteoporosis are mainly drug therapy and non-drug therapy. Medicine can only delay the loss of bone, but it can't restore the lost bone. At present, drugs mainly include drugs that inhibit bone resorption, drugs that promote osteogenesis, and traditional Chinese medicine. Drugs that inhibit bone resorption mainly include bisphosphonate, calcitonin, estrogen, BANKL monoclonal antibody, etc. Drugs that promote bone formation include thyroid hormone, calcium, vitamin D and simvastatin. Single traditional Chinese medicines mainly include Eucommia ulmoides Oliv., Epimedium Epimedium, etc. The prescriptions of traditional Chinese medicines mainly include Longmuzhuanggu granules, Xianlinggubao capsules, etc. Different drugs have different therapeutic effects and unique advantages. How to select the optimal drug to treat different types of osteoporosis has become the focus of clinical treatment. Besides, with the deepening of research and understanding on bone metabolism, the upgrading of existing drugs, the compatible use of drugs with different action mechanisms, new targeted drugs for cell function and gene, and the promotion of traditional Chinese medicine in China are all worthy of research. It is hoped that this research can provide new research ideas for pharmaceutical researchers and help to develop new clinical medication patterns and the R&D and marketing of new drugs.
VL - 10
IS - 3
ER -

Copy | Download

Author Information

Wenbo Hou

Basic and Clinical Medicine College, Shandong First Medical University, Jinan, China
Xi Wang

Basic and Clinical Medicine College, Shandong First Medical University, Jinan, China
Yanqin Lu

Biomedical Sciences College, Shandong First Medical University, Jinan, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Wenbo Hou, Xi Wang, Yanqin Lu. (2022). Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Science Discovery, 10(3), 191-199. https://doi.org/10.11648/j.sd.20221003.28

Copy | Download

ACS Style

Wenbo Hou; Xi Wang; Yanqin Lu. Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Sci. Discov. 2022, 10(3), 191-199. doi: 10.11648/j.sd.20221003.28

Copy | Download

AMA Style

Wenbo Hou, Xi Wang, Yanqin Lu. Research Progress of Osteoporosis Drugs and Their Mechanism of Action. Sci Discov. 2022;10(3):191-199. doi: 10.11648/j.sd.20221003.28

Copy | Download

@article{10.11648/j.sd.20221003.28,
  author = {Wenbo Hou and Xi Wang and Yanqin Lu},
  title = {Research Progress of Osteoporosis Drugs and Their Mechanism of Action},
  journal = {Science Discovery},
  volume = {10},
  number = {3},
  pages = {191-199},
  doi = {10.11648/j.sd.20221003.28},
  url = {https://doi.org/10.11648/j.sd.20221003.28},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20221003.28},
  abstract = {Osteoporosis (OP) is a systemic bone metabolic disease characterized by decreased bone mass, decreased bone density and easy fracture. The number of osteoporosis patients in the world has exceeded 200 million, and the incidence rate has exceeded 25%, ranking the sixth most common and frequently-occurring disease in the world. At present, the methods of treating osteoporosis are mainly drug therapy and non-drug therapy. Medicine can only delay the loss of bone, but it can't restore the lost bone. At present, drugs mainly include drugs that inhibit bone resorption, drugs that promote osteogenesis, and traditional Chinese medicine. Drugs that inhibit bone resorption mainly include bisphosphonate, calcitonin, estrogen, BANKL monoclonal antibody, etc. Drugs that promote bone formation include thyroid hormone, calcium, vitamin D and simvastatin. Single traditional Chinese medicines mainly include Eucommia ulmoides Oliv., Epimedium Epimedium, etc. The prescriptions of traditional Chinese medicines mainly include Longmuzhuanggu granules, Xianlinggubao capsules, etc. Different drugs have different therapeutic effects and unique advantages. How to select the optimal drug to treat different types of osteoporosis has become the focus of clinical treatment. Besides, with the deepening of research and understanding on bone metabolism, the upgrading of existing drugs, the compatible use of drugs with different action mechanisms, new targeted drugs for cell function and gene, and the promotion of traditional Chinese medicine in China are all worthy of research. It is hoped that this research can provide new research ideas for pharmaceutical researchers and help to develop new clinical medication patterns and the R&D and marketing of new drugs.},
 year = {2022}
}

Copy | Download